Beringea is an international venture capital and private equity firm dedicated to finding, funding and nurturing exceptional companies in growth industries. Founded in 1988, the firm currently has more than 60 portfolio companies in a range of emerging sectors, including media, health care and life sciences, Internet technologies, advanced manufacturing, clean tech and specialized consumer goods. With capital, experience and offices in the U.S. and U.K., Beringea is in a unique position to offer entrepreneurs and their management teams the resources to develop strategy, evaluate growth opportunities, solve problems and build value. Beringea is the co-manager of the Michigan Growth Capital Partners Funds in the U.S., as well as the ProVen VCT family of funds in the UK, among others.

Beringea

8VC enables industry transformation. In a wave of creative destruction, they believe emerging platforms will replace the decades-old technology infrastructure behind many industries, promoting greater innovation and prosperity.

Founded in 2000 as a private health insurance intermediary, iSelect's momentum over recent years has resulted in the addition of both life and motor insurance categories to its growing portfolio.  At iSelect  get that most people find insurance, utilities and personal finance boring. But iSelect understand that it’s really important to always get these things right.  As Australia’s life admin store, we’ll help you take care of the boring but important stuff. iSelect are proud of the service we provide to millions of Australians who seek our expert advice each year on some of life’s most important purchase decisions.  iSelect is much more than just another online comparison website. Comparing online is just the first step in our personalised comparison and expert advisory service. That’s why most of our customers choose to speak over the phone with one of our 500 highly-trained expert advisers at iSelect HQ.  Our dedicated departments cover all of life’s essentials, from choosing the right health or life insurance policy through to refinancing your home loan. iSelect can sort out your energy and broadband connections, and even take care of your car insurance.  iSelect compare and sell some of Australia’s biggest brands and are always adding more. With plenty of partners and thousands of policies, plans and products, we’ll give you the confidence to make the right call on some of the things that matter most. So you can spend time doing, well… anything else.  iSelect are proud to be 100% independently-owned, and unlike other comparison services, we are not owned by an insurance company and we do not own any of the companies or brands whose products we sell.  As well as our flagship iSelect brand, the iSelect Group also owns personal finance comparison website InfoChoice and energy comparison website Energy Watch.

iSelect

Founded in 2015, dRx Capital is Novartis' Digital Health Venture Fund investing in entrepreneurs transforming healthcare through data and digital technology. The fund invests in technology platforms improving access to healthcare and reimagining the practice of medicine, with a focus on AI & ML, big data, R&D optimization, patient care, and pharma supply chain and commercialization.

dRx Capital

Hewlett Packard Enterprise is an edge-to-cloud platform-as-a-service company that helps organizations accelerate outcomes by unlocking value from their data, everywhere. Built on decades of reimagining the future and innovating to advance how people live and work, HPE delivers unique, open, and intelligent technology solutions. HPE focuses primarily on enterprise-level solutions, including servers, storage, networking, software, and consulting services. They cater to various industries, offering technologies for data centers, cloud computing, edge computing, and other IT infrastructure needs. HPE has a long history in the technology sector and is known for its contributions to the development of computing and IT systems.

Hewlett Packard Enterprise

Argonautic Ventures is a group of micro-funds with varying investment theses and a group of general partners. Its innovative and flexible structure allows them to deploy into a portfolio of companies across industry and stages. Its venture funds identify targeted returns based on specific investment theses that their team is well-positioned to act upon. It focuses on a handful of emerging and mature industries where secular shifts are creating new business models that can scale quickly.  Its investment team has experience investing in several sectors related to technology, healthcare, and emerging markets.

Argonautic Ventures

Great North Ventures invests in entrepreneurs who are using the latest breakthrough technologies to innovate industries still dominated by analog processes. From Seed to Series B, the team provides guidance, capital, and connections. The fund looks for the best startups wherever they are located, because the next generation of great companies are growing outside of Silicon Valley. Built by successful founders, Great North Ventures values the ability to execute above all else.

Great North Ventures

York IE® is an advisory and venture capital firm that helps technology companies grow. York IE leverages a 200+ person global operating team, data and automation technology, and deep ecosystem relationships to provide advisory as a service across product, go-to-market, and finance and to selectively invest in early-stage B2B SaaS startups. Founders, operators, and investors at all stages rely on York IE to help build, scale and monetize their business. Fuel® Your Strategic Growth at York IE.

York IE

Intuitive Ventures focuses on early-stage start-ups and takes a long-term outlook to support companies to reach their major milestones. Through its inaugural $100 million funds and with leadership combining decades of investing and operational experience, the team cultivates strategic resources to drive financial returns and accelerate the future of minimally invasive care. Intuitive Ventures has already started deploying capital and is actively building its portfolio.

Intuitive Ventures

It all began in 2003, with a conversation outlining the inefficiencies in Angel investing in addition to the difficulties entrepreneurs face while raising start-up capital. Few investment groups specialize in investing $50k to $2 million in early-stage companies and even fewer bring a broad value-add network to support entrepreneurs. The Seraph Investor Network was founded with the vision of providing capital and support  in an expedient and efficient manner without geographic prejudice. Our Investor Network reaches 91+ cities and spans three continents. The reach provides valuable expertise to entrepreneurs and investors.  Seraph Group is comprised of a diverse group of business leaders, entrepreneurs, and technology leaders across wide array of different industries. By leveraging this expertise, Seraph Group is able to evaluate and invest in venture scalable opportunities across most industries. Investments range from $50K to $1.5 million and can participate along any financing stage of the company. While Seraph Group is comprised solely of angel investors, the investment process mimics a traditional venture capital firm where there is a fund managed by a small investment team. This pool of smart capital brings singular access to a prestigious group of individuals that are all invested in an entrepreneur's business and its success.  In today' market, companies have proven that only a relatively small amount of capital infusion, under $1 million, is enough to build a venture scalable business. However, most entrepreneurs will attest, that raising $500K to $1.5 million, is the hardest amount of capital to raise because it is too small for traditional venture firms. Seraph Group's focus is to fill this unmet need in the market for professional, smart capital.  The primary investment criteria for companies raising money is for it to be a venture-scalable business and not a life-style business. Seraph Group will consider investing in any round of financing and has often invested alongside later-stage venture firms.

Seraph Group

Novartis Venture Fund's primary focus is on the development of novel therapeutics and platforms. They balance the therapeutic focus with investments in medical devices, diagnostics, or drug delivery systems. In their investments, they look for unmet needs and clinical impact, novel proprietary science, an understanding of mechanism, management and board experience, and capital efficiency in the program. Novartis Venture Fund prefers to have their initial investment at the early stage to build the company and follow with additional investment in pace with the company's progress. Their approach involves larger focused investments, with anticipation of total investments up to USD 30 to 50 million per company over its life, but it can be as little as 100,000 USD to get started. They plan to increase their activities to lead or co-lead deals further and remain open to participating in larger syndicates.

Novartis Venture Fund

Pathfinder Partners is the sponsor of the Pathfinder family of opportunity funds. Pathfinder is a value investor applying an opportunistic and value-add approach to real estate investments which it can transform through additional capital infusions, institutional level management and property re-positioning. Pathfinder manages opportunity funds which own and invest in diversified portfolios of real estate assets as well as two funds targeting “for rent” and “for sale” residential properties. Pathfinder has acquired, defaulted loans, bank real estate-owned (“REO”) and value-add properties with estimated invested capital exceeding $725,000,000. Pathfinder focuses primarily on residential properties (both “for sale” and “for lease” as well as selected entitled residential land opportunities) and secondarily on commercial properties. Pathfinder seeks out special situations, including acquiring senior mortgages secured by real estate assets, acquiring properties from financial institutions or acquiring real estate from families and other long-term owners. Pathfinder’s primary target markets are in major metro areas in the western U.S., including California, Arizona, Colorado, Washington, Oregon and Texas. Pathfinder’s principals have been investing and advising on real estate and corporate finance transactions since the mid-1980s. Pathfinder operates in a straightforward and transparent manner and seeks long-term relationships with others who share their core values.

Pathfinder Partners

From spiraling healthcare costs, to the rise of chronic diseases, to feeding a growing global population, the world is facing a complex web of interrelated challenges. iSelect was created to help solve these problems, connecting investors with the innovative companies that are fixing the food and health systems while opening up access to investment opportunities that are making a real impact on the future of our world.

iSelect Fund

Their northern soul has national clout. Key Fund not only invests, it’s shaping the sector at large.   Over the years, Their ambitions have grown. We’ve widened Their geographical reach across the north, and are helping to shape new kinds of industry– all of which have Social Impact at their heart.   But, we’re not upping sticks and moving to London. The Capital is coming to us, as They funnel even more European and national investment to local communities.   Key Fund works in the gap where there is a cost to doing nothing – a cost to society, the Treasury, the tax payer, but more importantly, to Their communities.

Key Fund

Alumni Ventures Group provides high-quality, diversified venture portfolios to individual investors who previously haven't had access to VC. It helps accredited alums from top entrepreneurial schools invest together in the ventures of fellow alums. The firm backs companies with an alumni connection and an institutional lead investor with expertise in the space. AVG also offers focused funds that allow any accredited investor access to a venture portfolio, diversified by type, sector, stage, and geography. Beth Obermiller, Michael Madden, and Mike Collins co-founded the firm in Manchester, New Hampshire in 2013.

Alumni Ventures

Spike Ventures is a VC fund that invests in Stanford-connected companies.

Spike Ventures

Novalis Lifesciences LLC, is a globally acting venture capital firm focused on breakthrough technologies in Life Science. Founded and managed by Dr. Marijn E. Dekkers, current chairman of Unilever and former chief executive officer of Bayer AG and Thermo Fisher Scientific Inc., Novalis works with a diversified group of project-based specialists leading in their respective life science fields

Novalis LifeSciences

NVentures is a venture capital firm that invests in early-stage technology companies, focusing on innovations in various sectors. NVentures is the venture capital arm of NVIDIA.

NVentures

Invenshure is an incubator firm that invests in therapeutics, emerging platform technologies, and medical devices or imaging companies. It prefers to take an active role in the operation of the company, typically as Chief Executive Officer, President or Chief Operating Officer. Invenshure was founded in 2011 and headquartered in Minneapolis, Minnesota.

Invenshure

Microsoft is an American multinational corporation that develops, manufactures, licenses, supports, and sells a range of software products and services. Microsoft’s devices and consumer (D&C) licensing segment licenses the Windows operating system and related software, Microsoft Office for consumers, and the Windows Phone operating system. The company’s computing and gaming hardware segment provides Xbox gaming and entertainment consoles and accessories, second-party and third-party video games, and Xbox Live subscriptions; surface devices and accessories; and Microsoft PC accessories. Its phone hardware segment offers Lumia smartphones and other non-Lumia phones. Its D&C segment provides Windows Store, Xbox Live transactions, and Windows phone store; search advertising; display advertising; Office 365 Home and Office 365 Personal; first-party video games; and other consumer products and services as well as operating retail stores. Microsoft’s commercial licensing segments license server products, including Windows Server, Microsoft SQL Server, Visual Studio, System Center, and related Client Access Licenses (CALs); Windows Embedded; Windows operating system; Microsoft Office for business, including Office, Exchange, SharePoint, Lync, and related CALs; Microsoft Dynamics business solutions; and Skype. Its commercial segment offers enterprise services, including premier support services and Microsoft consulting services; commercial cloud comprising Office 365 Commercial, other Microsoft Office online offerings, Dynamics CRM Online, and Microsoft Azure; and other commercial products and online services. The company markets and distributes its products through original equipment manufacturers, distributors, and resellers, as well as online.

Microsoft

Gundersen Health System provides quality health services through a comprehensive health network.

Gundersen Health System

Flywheel.io

Flywheel is a data management and analysis platform built specifically for scientists and the researcher's workflow.  They empower research momentum by focusing on data and medical image capture, content management, scientific computation, and collaboration.  With reproducible research in mind, they combine open-source methods from top universities, a modern web user interface, and an extensible compute engine based on containerization technology. The result is a software platform to accelerate discovery and help researchers do science, not IT. Flywheel accelerates new scientific discoveries in life-science, biotech, and academic imaging research through cloud-scale collaboration. As a result, imaging researchers are able to avoid innovation bottlenecks, and accelerate discovery by doing more science, and less IT.

<div>Flywheel operates a cloud-based medical research data management and collaboration platform which captures and curates clinical data from multiple sources such as imaging, electronic health records (EHRs), digital pathology and omics, to enable further processing and accelerate the drug discovery and development process. Flywheel's cloud platform automates tasks such as handling data and allows scientists to focus on new discoveries. It also offers tools for analyzing and visualizing data and can work with other AI and machine-learning platforms.</div>

Artificial intelligence is identifying and testing new therapies faster than ever.

AI Drug Discovery

Flywheel

Flywheel.io on LinkedIn: #siim24 #siim2024 #imaging #ai #imaginginnovation #healthcareinformatics

Azure

Flywheel, a prominent medical imaging AI platform, has introduced its software-as-a-service (SaaS) data management solution on Microsoft Azure.

SaaS (Software-as-a-Service) companies aggregating and analyzing biomedical data with the help of AI to generate insights across the drug development pipeline.

NVIDIA

Flywheel, a medical imaging artificial intelligence (AI) development platform is integrated with NVIDIA MONAI, part of the NVIDIA AI Enterprise software platform, and Azure Machine Learning Studio for development and deployment of production-grade AI applications.

Genentech

To accelerate drug discovery, Roche and Genentech have integrated Flywheel's cloud-scale informatics platform to ingest, classify, standardize, curate, and analyze medical imaging data, enabling rapid access to high-quality images for complex analysis and machine learning.

Siemens Healthineers

Flywheel will deliver a cloud-based research collaboration solution on the Siemens Healthineers teamplay digital health platform

<div>
 
 Flywheel operates a cloud-based medical research data management and collaboration platform which captures and curates clinical data from multiple sources such as imaging, electronic health records (EHRs), digital pathology and omics, to enable further processing and accelerate the drug discovery and development process. Flywheel's cloud platform automates tasks such as handling data and allows scientists to focus on new discoveries. It also offers tools for analyzing and visualizing data and can work with other AI and machine-learning platforms.
 
 
 Key customers and partnerships
 
 
 The company&rsquo;s services are targeted at companies in life sciences, clinical research, imaging research, and AI health development markets. Research institutions such as Stanford University, University of Pennsylvania, University of Michigan, and Massachusetts General Hospital, and Boston Children&rsquo;s Hospital, and Swiss pharma giant Roche and its member company Genentech (
 <a href="https://sp-edge.com/updates/6854">
 November 2021
 </a>
 ) are among its clientele.
 
 
 In 
 <a href="https://sp-edge.com/updates/24331">
 November 2023
 </a>
 , the company collaborated with Microsoft and NVIDIA to launch a SaaS data management solution on Miscrosoft Azure.
 
 
 Funding and financials
 
 
 The company raised USD 54 million In a Series D funding round in June 2023 led by Novalis LifeSciences and NVentures. The proceeds were earmarked to expand its reach into new markets and geographies, especially Europe. 
 
</div>

<div>
 
 HiberCell is a biotechnology company that develops novel therapies focused on oncology. It entered the AI drug discovery space when it acquired AI genomics analysis company Genuity Science (and its subsidiaries in Iceland and Ireland) in August 2021.&nbsp;
 
 
 Genuity Science&rsquo;s solutions include end-to-end therapeutic discovery and development services such as building custom disease datasets, discovering and prioritizing targets, identifying biomarkers, and optimizing clinical trials. Genuity Science leverages its AI-powered platform to manage, process, and analyze genomic data. HiberCell intends to use Genuity Science&rsquo;s AI/ML capabilities to advance its oncology pipeline of five programs, of which one has reached the Phase 2 clinical trial stage.
 
 
 As of March 2024, the company&rsquo;s pipeline included three drug candidates, namely: 1) HC-7366, targeting the general control nonderepressible 2 (GCN2) kinase as part of the integrated stress response (ISR) signaling pathway; 2) HC-5404, aimed at inhibiting the PKR-like endoplasmic reticulum kinase (PERK) involved in the unfolded protein response (UPR) signaling pathway; and 3) odetiglucan, a therapy targeting tumor-immune interactions within the tumor microenvironment​.&nbsp;
 
 
 Key customers and partnerships
 
 
 In December 2023, HiberCell and Merck &amp; Co partnered to conduct a Phase Ib trial to evaluate the combination therapy of belzutifan and HC-7366 for treating clear cell renal cell carcinoma. Further, in January 2021, the company partnered with Biodesix to develop an enzyme-linked immunosorbent assay as a companion diagnostic test.
 
 
 Funding and financials
 
 
 In 
 <a href="https://hibercell.com/news/hibercell-closes-67-4-million-series-b-financing-and-secures-30-million-debt-facility-from-hercules-capital/">
 May 2021
 </a>
 , HiberCell completed a Series B financing round, raising USD 67.4 million, and secured an additional USD 30 million in debt financing from Hercules Capital. The funds were expected to be used for clinical advancement of its novel therapeutic candidates. 
 
</div>

HiberCell

<div>
 
 Arbor Biotechnologies specializes in gene editing to develop novel therapeutics for a variety of indications, starting with liver-related diseases. It operates an AI-powered biodiscovery platform to discover novel CRISPR enzymes, which are sequences of repeating genetic code. To do this, its platform deploys computational search techniques, genome sequencing, gene synthesis, and high-throughput screening. This can eventually be turned into drugs or even applied to agriculture and other industrial uses. In 2018, the company announced the discovery of Cas13d, a new type of gene editing enzyme that helps to alter RNA to treat genetic diseases.&nbsp;
 
 
 As of February 2024, the company had five internal drug discovery programs, of which one was in the IND-enabling stage. It also has multiple collaborative programs under development focused on oncology and various other therapeutic areas.
 
 
 Key customers and partnerships
 
 
 The company has a long-standing partnership with Vertex Pharmaceuticals since
 <a href="https://www.businesswire.com/news/home/20190103005194/en/Vertex-and-Arbor-Biotechnologies-Establish-Collaboration-to-Discover-Novel-Proteins-to-Advance-Discovery-of-Gene-Editing-Therapies">
 January 2019
 </a>
 , which focused on developing gene-editing treatments for cystic fibrosis and four other diseases. The alliance was further extended in 
 <a href="https://www.biospace.com/article/vertex-and-arbor-strike-a-1-2-billion-deal-for-gene-editing-programs/">
 August 2021
 </a>
 and 
 <a href="https://sp-edge.com/updates/15741">
 January 2023
 </a>
 .&nbsp;
 
 
 Other partnerships included a collaboration with 
 <a href="https://www.prnewswire.com/news-releases/arbor-biotechnologies-announces-collaboration-with-ginkgo-bioworks-to-advance-the-discovery-and-development-of-precision-gene-editors-302011991.html">
 Ginkgo Bioworks
 </a>
 (December 2023) to leverage Ginkgo's R&amp;D services to further optimize Arbor's novel precision editors, a non-exclusive licensing agreement with 
 <a href="https://www.globenewswire.com/news-release/2022/02/08/2380680/0/en/EdiGene-and-Arbor-Biotechnologies-Announce-Worldwide-Non-exclusive-License-Agreement-to-Advance-Ex-Vivo-Engineered-Cell-Therapy-Programs.html">
 EdiGene
 </a>
 (February 2022) to leverage Arbor&rsquo;s platform for ex vivo oncology therapies, a strategic research and non-exclusive licensing agreement with 
 <a href="https://investors.tcr2.com/news-releases/news-release-details/tcr2-therapeutics-and-arbor-biotechnologies-establish">
 TCR2 Therapeutics
 </a>
 (January 2022) to develop allogeneic TRuC T-cell therapies using Arbor&rsquo;s CRISPR technology, and a license agreement with 
 <a href="https://www.lonza.com/news/2020-12-23-14-00">
 Lonza
 </a>
 (December 2020) to use Arbor&rsquo;s gene-editing technology for Lonza&rsquo;s bioproduction products and services.
 
 
 Funding and financials
 
 
 In its latest Series B funding round in November 2021, which was led by Ally Bridge Group, TCG Crossover, and Temasek, Arbor Biotechnologies raised USD 215 million. The proceeds of the round were earmarked to fuel the company&rsquo;s clinical development pipeline.
 
</div>

Arbor Biotechnologies

Based in the UK, Arctoris provides an automated drug discovery platform, offering fully validated research and development (R&amp;D) processes under an Experiments-as-a-Service model. The company works with biotechnology companies, AI drug discovery companies, pharma and academic institutions enabling these institutions to run experiments in Arctoris’s platform and provides on-demand access to a broad scale of datasets for AI drug discovery companies to train their algorithms.

Arctoris

<div>
 
 Frontier Medicines leverages AI/ML technologies to develop treatments for cancer-causing proteins that are dismissed by traditional pharma companies as undruggable.&nbsp;
 
 
 The company has a proprietary chemoproteomic platform which entails an approach based on the interaction of small-molecule compounds and proteins to screen a large number of targets and combine them with a protein database that contains more than 150,000 novel binding pockets (hotspots). This enables it to access 90% of the human proteome that were not previously targeted due to lack of hotspots. The platform&rsquo;s AI/ML engine incorporates a library of diverse compounds, a hotspot map that serves as the starting point for understanding the druggability of a potential therapeutic target, and lead design and generation.&nbsp;
 
 
 The company focuses on oncology and immunology target and, as of February 2024, it had five wholly-owned therapeutic programs and three AbbVie-partnered programs in its pipeline. All programs were in their discovery stage, except the company&rsquo;s lead candidate, FMC-376 (activated and inactivated forms), focused on treating different cancer types, including non-small cell lung cancer (NSCLC), colorectal carcinoma (CRC), and pancreatic ductal adenocarcinoma (PDAC), which is in the IND-enabling stage.
 
 
 Key customers and partnerships
 
 
 The company entered a USD 100 million partnership with 
 <a href="https://news.abbvie.com/2020-12-02-AbbVie-and-Frontier-Medicines-Establish-Global-Partnership-to-Discover-and-Develop-Novel-Therapies-and-E3-Degraders-Against-Difficult-to-Drug-Targets">
 AbbVie
 </a>
 In December 2020 to develop small-molecule therapeutics against hard-to-drug protein targets including around 600 E3 ligases (the enzymes that drive the ubiquitination and degradation of proteins.&nbsp;
 
 
 Funding and financials
 
 
 In July 2021, the company raised USD 88.5 million in a 
 <a href="https://sp-edge.com/updates/4347">
 Series B
 </a>
 funding round co-led by Woodline Partners LP and RA Capital Management, with equal participation from Deerfield Management Company. The proceeds were earmarked for advancing the company&rsquo;s drug pipeline and expanding operations in Boston, where its new facility was to complement the company&rsquo;s headquarters in California. 
 
</div>

Frontier Medicines

<div>
 
 Verge Genomics is a biotechnology company engaged in developing therapeutics for neurological diseases using human genomics and AI to accelerate drug discovery. The main target areas are Amyotrophic Lateral Sclerosis (ALS), Parkinson&rsquo;s Disease (PD), and Frontotemporal Dementia (FTD).&nbsp;
 
 
 It has built a proprietary all-human platform (unlike standard clinical trials that rely on animal data), called CONVERGE, that uses data sets from brain tissue samples of deceased patients with ALS and PD. While most drugs target only one gene at a time, the company claims its technology can identify hundreds of genes that cause disease and develop drugs that target all the genes at the same time. The company uses AI technology to optimize the drug discovery process as a whole.
 
 
 As of March 2024, Verge had one drug candidate in the clinical stage (Phase I) and 10 drug candidates in the discovery stage.&nbsp;
 
 
 Key customers and partnerships
 
 
 The company has partnerships with various tissue banks (such as Harvard University and University of Miami Miller School of Medicine) and several educational institutes and foundations (such as Target ALS, Answer ALS) that enabled its drug discovery platform.&nbsp;
 
 
 In addition, the company&rsquo;s customers include several pharmaceutical companies, such as 1) 
 <a href="https://www.vergegenomics.com/news-blog/verge-genomics-announces-research-collaboration-with-the-sheffield-institute-for-translational-neuroscience">
 Sheffield Institute for Translational Neuroscience (SITraN)
 </a>
 to accelerate the validation of novel drug targets and screening of drug compounds for Parkinson's disease (February 2021), 2) 
 <a href="https://sp-edge.com/updates/4146">
 Eli Lilly
 </a>
 to research and develop novel therapies to treat ALS (July 2021), 3) 
 <a href="https://sp-edge.com/updates/21707">
 Alexion
 </a>
 to identify novel drug targets for rare neurodegenerative and neuromuscular diseases (September 2023), and 4) 
 <a href="https://www.vergegenomics.com/news-blog/verge-genomics-and-the-pritzker-neuropsychiatric-disorders-research-consortium-form-cutting-edge-schizophrenia-research-collaboration">
 Pritzker Neuropsychiatric Disorders Research Consortium
 </a>
 to analyze data from schizophrenic patient&rsquo;s brain tissue with Verge&rsquo;s technology (October 2023).
 
 
 Funding and financials
 
 
 In December 2021, Verge raised USD 98 million in an oversubscribed 
 <a href="https://sp-edge.com/updates/7426">
 Series A
 </a>
 funding round led by BlackRock. The funds were used to scale up its pre-clinical and clinical candidate programs in the pipeline and enhance its lead therapeutics through clinical testing. 
 
</div>

Verge Genomics

SaaS (Software-as-a-Service) companies providing their ML platform to other pharma companies for drug discovery services such as target selection, validation and lead optimization.

SaaS (Software-as-a-Service) companies providing their ML platform to other pharma companies to design and run preclinical experiments.

SaaS (Software-as-a-Service) companies providing their ML platform to other pharma companies to identify biomarkers (measurable biological signs used to determine disease progression) and predict drug response.

Biotechnology companies that have integrated AI as a core component of their in-house drug development process. They typically have a few in-house drug development programs, and also collaborate with pharma companies to develop certain drugs.

Includes companies that use GenAI as a core part of their product offering for drug discovery & development

Companies leverage GenAI to support drug discovery through accelerated drug designing

Companies offer AI/ML-based SaaS products to accelerate the discovery and development of novel therapeutics

Offers AI/ML-based solutions to accelerate drug discovery and development

INCUMBENTS_PRESENT

PROMINENT_CATEGORY

<div>
Medical imaging AI development platform Flywheel has teamed up with Microsoft and NVIDIA to introduce a SaaS data management solution. The collaboration aims to leverage Flywheel's infrastructure and Microsoft Azure's services to facilitate data preparation for AI model development. The objective is to speed up the identification of standardized, high-quality datasets and streamline the management, curation, and analysis of medical imaging data. Moreover, the partnership enables the integration of Flywheel's solution with mPower Clinical Analytics by Nuance, improving patient cohort discovery and enhancing radiology image data.
</div>

Flywheel

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless